Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only
      Prescribing Information
      BOTOX® SMPC
      RESOURCES

      +30 YEARS' GLOBAL EXPERIENCE
      ACROSS MULTIPLE INDICATIONS1-4

       

      UROLOGY

      BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.5
      Prescribing Information
      BOTOX® SMPC
      RESOURCES

      +30 YEARS' GLOBAL EXPERIENCE ACROSS MULTIPLE INDICATIONS1-4

      UROLOGY

      BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.5

      UK-BUO-240005. DOP: April 2024.

      Understanding and addressing the unmet need in urology: Neurogenic Detrusor Overactivity (NDO)

      Prevalence of NDO

      Spinal lesions caused by trauma, such as spinal cord injury, or by a progressive neurological condition, such as multiple sclerosis can lead to NDO.

      NDO is a complex, multi-symptom syndrome that can be difficult to treat, requiring appropriate effective management - including treatment or referrals to improve patient outcomes

      The aetiology of NDO10,11

      Aetiologies

      • Spinal cord injury
      • Spina bifida
      • Multiple sclerosis
      • Stroke
      • Parkinson’s disease
      • Cerebrovascular accidents
      • Other

      Common bladder storage symptoms and definitions11,12

      Table 2

      Consequences of untreated NDO13-15

      X1470 NDO UK BOTOX Sales Aid - New Branding_4 1

      Adapted from Tubaro, 2004.13

      NDO is a complex, multi-symptom syndrome that can be difficult to treat, requiring appropriate effective management - including treatment or referrals to improve patient outcomes

      MS, multiple sclerosis; NDO, neurogenic detrusor overactivity; QoL: quality of life; SCI, spinal cord injury.

      DIAGNOSING NDO

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc. Accessed April 2024
      6. Aspire News. Spinal cord injury. Available at: https://www.aspire.org.uk/news/every-four-hours. Accessed April 2024.
      7. Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19:S191-S196
      8. Litwiller S E, Frohman E M and Zimmern P E. Multiple sclerosis and the urologist. J Urol. 1999;161:743–757
      9. MS Society. MS Prevalence Report January 2020. Available at: https://www.mssociety.org.uk/. Accessed April 2024
      10. Abrams P et al. Incontinence: 6th Edition 2017;50
      11. Blok B, et al. EAU Guidelines on Neuro-Urology 2022. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2022.pdf. Last accessed April 2024. 
      12. Castro Diaz D, Robinson D et al. Patient-reported Outcome Assessment. Abrams P et al. Incontinence: 6th Edition. 2017:50
      13. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(suppl 6A);2–6
      14. de Seze M, Ruffion A et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis. 2007;13:915–928
      15. Goldmark E, Niver B and Ginsberg D A. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15:448

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc /product/859/smpc. Accessed April 2024
      6. Aspire News. Spinal cord injury. Available at: https://www.aspire.org.uk/news/every-four-hours. Accessed April 2024.
      7. Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19:S191-S196
      8. Litwiller S E, Frohman E M and Zimmern P E. Multiple sclerosis and the urologist. J Urol. 1999;161:743–757
      9. MS Society. MS Prevalence Report January 2020. Available at: https://www.mssociety.org.uk/. Accessed April 2024
      10. Abrams P et al. Incontinence: 6th Edition 2017;50
      11. Blok B, et al. EAU Guidelines on Neuro-Urology 2022. Available from: https://d56bochluxqnz.cloudfront.net /documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2022.pdf. Last accessed April 2024. 
      12. Castro Diaz D, Robinson D et al. Patient-reported Outcome Assessment. Abrams P et al. Incontinence: 6th Edition. 2017:50
      13. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(suppl 6A);2–6
      14. de Seze M, Ruffion A et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis. 2007;13:915–928
      15. Goldmark E, Niver B and Ginsberg D A. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15:448

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on [email protected] 

       

      Date of preparation: April 2024. UK-BUO-240006.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.